Keywords: Pfizer, Revatio, Savient, Krystexxa, PAH, Chronic gout, Commission, EMA

EC approves Pfizer’s Revatio for PAH in children; Savient files Krystexxa with EMA

Article | 06 May 2011

Print This

US drugs behemoth Pfizer (NYSE: PFE) yesterday revealed that Revatio (sildenafil citrate, which is also the active ingredient of its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in